Eton Pharmaceuticals, Inc. (ETON)
ETONNASDAQ-GMBiotechnology: Pharmaceutical Preparations
$68.40
+1.84 (+2.76%) today
Pre-market, Nov 11, 4:00 PM ET
- Market cap
- $1.97bn
- P/E
- 45.3
- EPS, last 4 quarters
- $1.51
- Dividend yield
- –
- Day range
- –
- 52-week range
- $14.27 to $68.38
- Average volume
- –
- Previous close
- $66.56
Analysts
3 coveringStrong Buy3 buy, 0 hold, 0 sell
Targets a year out average $80.75, +18.1% from here
Earnings
next estimate $0.3900Next report
Dec 2025
-58.3%
Mar 2026
-50.0%
Jun 2026
+218.2%
Sep 2026
+211.8%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $21.28m | $24.27m | $37.59m | $57.92m |
| Gross profit | $13.10m | $14.73m | $25.41m | $44.30m |
| Operating income | $2.46m | $2.41m | $12.79m | $23.01m |
| Net income | $1.48m | $1.55m | $11.58m | $35.25m |
Last four quarters: revenue $141.06m, margin 35.4%, free cash flow $38.22m
News
8 latest- Eton Pharmaceuticals Announces Preliminary ET-700 Pilot Study ResultsFintel · 6 days ago
- Eton Q3 Earnings Call Highlights Growth and Pipeline ExpansionZacks · 6 days ago
- Eton Pharma (ETON) Q3 2026 Earnings Call TranscriptThe Motley Fool · 6 days ago
- Eton Pharmaceuticals Q3 Earnings Call HighlightsMarketBeat · 6 days ago
- Eton Pharmaceuticals, Inc. (ETON) Q3 Earnings and Revenues Surpass EstimatesZacks · 6 days ago
- ETON Gears Up to Report Q3 Earnings: What Can Investors Expect? Zacks · Nov 2, 2026
- Eton Announces New Program For Mecasermin In Epileptic Spasms; Phase 2 Planned For Q1 '27 RTTNews · Nov 2, 2026
- Eton Announces New Development Program To Evaluate Mecasermin Injection RTTNews · Nov 2, 2026
The company
Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has twelve rare disease products: KHINDIVI , INCRELEX, ALKINDI SPRINKLE, DESMODA, GALZIN, HEMANGEOL, PKU GOLIKE, IMPAVIDO, LIBERVANT, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has six additional product candidates in late-stage development: ASN-001, AMGLIDIA, ET- 700, ET - 800, ET -900, and ZENEO hydrocortisone autoinjector.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- etonpharma.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.